Rybelsus®

Semaglutide

Rybelsus compresse (semaglutide) è un farmaco di prescrizione utilizzato negli adulti con diabete mellito di tipo 2 per ridurre i livelli di zucchero nel sangue. Rybelsus può essere prescritto quando altri farmaci per il diabete sono stati provati senza successo e deve essere usato insieme alla dieta e all'esercizio fisico. Le compresse di Rybelsus agiscono per abbassare i livelli di zucchero nel sangue (glucosio) aumentando la quantità di insulina rilasciata e diminuendo la secrezione di glucagon. Questo medicinale può anche rallentare lo svuotamento gastrico dopo aver mangiato.
more
Confezione Per pillola Prezzo Risparmio Ordine
90 tablet
Free AirMail shipping Hot
€ 14.25
€ 1282.72€ 14.25
€ 170.94
60 tablet
Free AirMail shipping Hot
€ 15.20
€ 912.14€ 15.20
€ 56.96
30 tablet
Free AirMail shipping Hot
€ 16.15
€ 484.55€ 16.15
Confezione Per pillola Prezzo Risparmio Ordine
90 tablet
Free AirMail shipping Hot
€ 17.10
€ 1539.28€ 17.10
€ 85.42
60 tablet
Free AirMail shipping Hot
€ 17.58
€ 1054.67€ 17.58
€ 28.46
30 tablet
Free AirMail shipping Hot
€ 18.05
€ 541.57€ 18.05
Confezione Per pillola Prezzo Risparmio Ordine
90 tablet
Free AirMail shipping Hot
€ 20.43
€ 1838.59€ 20.43
€ 85.42
60 tablet
Free AirMail shipping Hot
€ 20.90
€ 1254.22€ 20.90
€ 28.46
30 tablet
Free AirMail shipping Hot
€ 21.38
€ 641.34€ 21.38
Rybelsus

Marca (Marchi)

Fabbricante

  • Novo Nordisc India Pvt. Ltd

Diseases

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.